Effects of topiramate on inflammatory parameters in migraine prophylaxis

Basit Öğe Kaydı
dc.contributor.authorÖzdemir, Hasan Hüseyin
dc.contributor.authorDönder, Ahmet
dc.date.accessioned2022-05-13T06:33:34Z
dc.date.available2022-05-13T06:33:34Z
dc.date.issued2022en_US
dc.departmentMAÜ, Meslek Yüksekokulları, Sağlık Hizmetleri Meslek Yüksekokulu, Tıbbi Hizmetler ve Teknikler Bölümüen_US
dc.description.abstractAim: Many medical agents are used in migraine prophylaxis. Topiramate is used as a first-line treatment option for migraine prophylaxis. It has different side effects, but its effects on inflammatory markers are unknown. In this study, we investigate the effects of topiramate in neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and C-reactive protein (CRP) with migraine patients without aura. Method: In this retrospective study, 60 healthy controls and 78 patients who were followed up and had a diagnosis of migraine and took a topiramate therapy were evaluated pretreatment, 3rd, and 6th months after treatment. The number of days with pain, duration of pain, Migraine Disability Assessment Test (MIDAS), and Visual Analog Scale (VAS) scores of the patients were evaluated before treatment and during the controls. Results and Conclusions: A significant decrease was observed in the painful days, duration of pain, MIDAS, and VAS scores in the evaluations in the 3rd and 6th month periods after the initiation of topiramate. Thrombocytopenia developed in one patient, generalized paresthesia in two patients, and treatment was discontinued for these patients. NLR, PLR, and CRP values before the topiramate treatment were statistically higher than the values at 3rd and 6th months of treatment. Neutrophil, platelet, and lymphocyte counts also decreased during treatment. There was no statistically significant difference between inflammatory parameters and number of days with pain, duration of pain, MIDAS, and VAS scores. NLR, PLR, and CRP values decreased topiramate therapy. Studies are needed to evaluate the anti-inflammatory effectiveness of topiramate in the treatment of migraine.en_US
dc.identifier.citationÖzdemir HH, Dönder A. (2022). Effects of topiramate on inflammatory parameters in migraine prophylaxis. Neurol Clin Neurosci. 2022;10:155–159. doi:10.1111/ncn3.12592en_US
dc.identifier.scopus2-s2.0-85125921195en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1111/ncn3.12592
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000766223100001?AlertId=d383397b-4355-449e-9419-70f9e0e77c15&SID=EUW1ED0E58wM5lk4RVxnH4bMZvdZf
dc.identifier.urihttps://hdl.handle.net/20.500.12514/3100
dc.identifier.wosWOS:000766223100001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWiley Online Libraryen_US
dc.relation.ispartofNeurol Clin Neuroscien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectC-reactive protein, migraine, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, topiramateen_US
dc.titleEffects of topiramate on inflammatory parameters in migraine prophylaxisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Neurology Clinical Neurosc - 2022 - zdemir - Effects of topiramate on inflammatory parameters in migraine prophylaxis.pdf
Boyut:
328.78 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text - Article
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıbbi Hizmetler ve Teknikler Bölümü Koleksiyonu